A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Qishenyiqi Drop Pills in Improving the Prognosis of Heart Failure Patients With Reduced Ejection Infarction
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 5,380
- 试验地点
- 1
- 主要终点
- Time to the occurrence of cardiovascular (CV) death or heart failure (HF) re-hospitalization.
研究概览
简要总结
This is a multicenter, randomized, double-blind, placebo-controlled study including patients with ejection fraction decreased heart failure under standardized treatment, to evaluate QiShenYiQi (QSYQ) dropping pill's curative effect in reducing cardiovascular death and heart failure rehospitalization compared with placebo.
详细描述
This is a prospective, large-scale samples, randomized, double-blind, placebo parallel-controlled, multicenter study to evaluate QSYQ's curative effect in reducing cardiovascular death and heart failure rehospitalization in patients with ejection fraction decreased heart failure（LVEF≤40%）under standardized treatment. The results will provide clinical evidence for combined treatment of traditional Chinese medicine and western medicine in ejection fraction decreased heart failure.
There are two treatment groups in the study, which are the treatment group with standard treatment + QSYS (oral use, 1 bag each time, three times a day) , and the control group with standard treatment + placebo (oral use, 1 bag each time, three times a day) .
The subjects are patients with ejection fraction decreased (≤40%) heart failure (NYHA II-IV). The sample size is 5380. For the primary end event, type I error is bilateral 0.05, and POWER was 0.8. The CV death and the HF readmission rate in the trial control group is 15%, and 12.7% in the experimental group. The trial cycle is about 3 years. A total of 4373 subjects will be assigned to the experimental group and the control group at a proportion of 1:1. The primary endpoint was expected to be 1211 cases. Taking into account the annual rate of lost to follow-up is about 18%, the final sample cases is 5380. During the treatment period and extends to at most 2weeks after treatment, patients will get examination including interviews (direct inquiries about the occurrence of adverse events and the situation of taking drugs), physical examination, body weight and the ECG. Laboratory parameters to evaluate clinical safety, such as routine blood, serum creatinine and urea nitrogen, electrolyte (serum potassium, sodium and chloride) and liver enzymes will be taken regularly. Researchers need to record and evaluate any occurrence of adverse events (AE) or serious adverse event (SAE) and its relevance to study medicine.
The primary endpoint is to evaluate whether QSYQ can reduce cardiovascular death and heart failure rehospitalization in chronic heart failure patients with reduced ejection infarction (HFREF) compared with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ability to understand the requirements of the study and willingness to provide written informed consent.
- •Male or female subjects aged ≥ 18 years
- •Patients with ejection fraction decreased heart failure (NYHA II-IV, Echocardiography with Simpson method within four weeks and NT-proBNP within two weeks before random) （1）35%≤LVEF≤40% ; NT-proBNP≥900pg/ml, patients with renal dysfunction (glomerular filtration rate <60 ml/min/1.73m2）or atrial fibrillation, the NT-proBNP should be ≥1200 pg/ml； （2）LVEF<35% (Simpson method); NT-proBNP≥600pg/ml, patients with renal dysfunction (glomerular filtration rate <60 ml/min/1.73m2）or atrial fibrillation, the NT-proBNP should be ≥900 pg/ml.
- •A history of hospitalization or emergency treatment for heart failure in the past two years and a diagnosis of heart failure at least one month ago
- •The use of medications in line with the recommendation of China heart failure treatment guidelines for at least 4 weeks. (Please confirm that all the following conditions must be met) : Including a ACEI or ARB, and a beta- blocker, unless contraindicated or not tolerated. The doses should reach the target dose recommended by the guideline or the maximum dose that the patient can tolerate, and the doses should not be changed within one months prior to screening and randomization (patients not take such drugs according to the guidelines, should be recorded).
排除标准
- •Acute decompensated HF with hemodynamic instability, mechanical hemodynamic support or invasive mechanical ventilation within 14 days of randomization, using intravenous positive inotropic drugs, vasoactive drugs and intravenous diuretics within 7 days before randomization.
- •Poorly controlled hypertension, defined as resting systolic blood pressure≥180mmHg and /or diastolic blood pressure ≥110mmHg assessed on two separate occasions prior to randomization.
- •Liver transaminase (ALT or AST), bilirubin more than 3 times the upper limit of normal not caused by heart failure, glomerular filtration rate<15ml/min/1.73m
- •Hemoglobin concentration ≤ 9.0g/dl and/or have blood system disease.
- •Valvular heart disease, congenital heart disease without surgery.
- •Cardiac shock.
- •Hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, other secondary and invasive cardiomyopathy.
- •Active myocarditis.
- •Constrictive pericarditis, other pericardial diseases.
- •Syncope within 3 months.
- •Symptomatic bradycardia or II or III degrees heart block without a pacemaker.
- •Ventricular arrhythmias affecting hemodynamics.
- •Cardiac resynchronization therapy implanted pacemaker (CRT-P) or cardiac resynchronization therapy defibrillators (CRT-D) within 6 months, or upgrade the existing conventional pacemaker or implantable implantable defibrillator (ICD) to the CRT device, or have the intention to implant similar devices.
- •Occurred within 3 months: acute coronary syndrome, stroke, transient ischemic attack; Heart, carotid artery or other large vascular surgery; Percutaneous coronary intervention (PCI) or carotid artery angioplasty, CABG or other cardiac surgery.
- •Major surgery within 6 months prior to randomization.
- •Has a history of heart transplantation or are waiting for transplants or using left ventricular assist device (LVAD) or have intention to heart transplant (waiting for transplants) or implant the VAD.
- •Severe chronic obstructive pulmonary disease, pulmonary heart disease, sever pulmonary vascular disease, pulmonary hypertension caused by autoimmune disease, any type of severe pulmonary hypertension.
- •History of major organ transplant (such as lung, liver, heart, bone marrow, kidney).
- •Patients with serious primary diseases of liver, kidney, hematopoietic system, nervous system, endocrine system, and patients with cancer or mental illness.
- •Life expectancy is less than 1 year.
- •Known allergy to any study drug.
- •Participants in other clinical studies within 1 month.
- •Patients who are taking Chinese medicine and proprietary Chinese medicine with similar ingredients of QSYQ.
- •Women who have developed pregnancy (pregnancy test positive) or during lactation; women of childbearing age have not taken adequate contraceptive measures.
- •According to the researchers, patients could not complete the study or fail to comply with the requirements of the study (due to management or other reasons).
研究组 & 干预措施
The Treatment Group
standard treatment + Qishenyiqi dropping pills (QSYQ) (oral use, 1 bag each time, three times a day)
干预措施: Qishenyiqi dropping pills (Drug)
The Control Group
standard treatment + placebo (oral use, 1 bag each time, three times a day).
干预措施: Placebo (Drug)
结局指标
主要结局
Time to the occurrence of cardiovascular (CV) death or heart failure (HF) re-hospitalization.
时间窗: up to 30 months
Compared with placebo, whether QSYQ prolong the occurrence of CV death or HF re-hospitalization of patients with chronic heart failure with lower ejection fraction (HFrEF). The treatment arm with the delayed events happening will be deemed as having a successful response.
次要结局
- Change from baseline to week 48 for the 6 minutes walking distance.(from baseline to week 48)
- Time to the occurrence of all-cause death.(up to 30 months)
- Time to the occurrence of all-cause death or HF re-hospitalization.(up to 30 months)
- Time to the occurrence of composite endpoint.(up to 30 months)
- Time to the first occurrence of HF hospitalization.(up to 30 months)
- Time to the occurrence of CV death.(up to 30 months)
- Time to the occurrence of total HF re-hospitalization.(up to 30 months)
- Change from baseline to week 48 for the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score.(from baseline to week 48)
研究者
Jian Zhang
the director of the heart failure center
Chinese Academy of Medical Sciences, Fuwai Hospital